



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/070,489

09/17/2002

Travis Robert Glare

24747-1104US

6955

35489

7590

02/11/2005

HELLER EHRMAN WHITE & MCAULIFFE LLP
275 MIDDLEFIELD ROAD
MENLO PARK, CO 94025-3506

EXAMINER

KUBELIK, ANNE R

ART UNIT

PAPER NUMBER

1638

DATE MAILED: 02/11/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/070,489

Applicant(s)

GLARE ET AL.

Examiner

Anne R. Kubelik

Art Unit

1638

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 15 November 2004.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-48 is/are pending in the application.
- 4a) Of the above claim(s) 15, 17-40 and 44-48 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-14, 16 and 41-43 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 17 September 2002 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☒ Other: sequence search results.

DETAILED ACTION

1. Applicant's election with traverse of Group I (claims 1-14, 16 and 41-43) in the reply filed on 15 November 2004 is acknowledged.

The traversal is on the grounds that the restriction between groups I and IV should be withdrawn because the probes and primers of group IV are fragments of the nucleic acid of group I and because all group members are also nucleic acids; thus, groups I and IV share the same technical feature and form a single inventive concept (response pg 2). This is not found persuasive because the nucleic acids of groups I and IV have different nucleotide sequences and would be different products. Lack of unity practice limits examination to one product, one method of making the product and one method of using the product.

Applicant urges that that the restriction between groups II and III should be withdrawn because both are drawn to proteins, as the ligand of group III may be a protein; thus, groups II and III share the same technical feature and form a single inventive concept (response pg 2). This is not found persuasive because the ligand could be something other than a protein; thus, groups II and III would not share the same technical feature of being proteins. Furthermore, the protein of group II and any protein ligand that binds to it would have different amino acid sequences and would be different products. Lack of unity practice limits examination to one product, one method of making the product and one method of using the product.

Applicant urges that that none of the references cited in the restriction teach or disclose SEQ ID NO:1 (response pg 2-3). This is not found persuasive because the claims appear to be drawn to any nucleic acid with 75% or 50% homology to SEQ ID NO:1 or any fragment thereof (see objections and rejections below). The cited references teach such nucleic acids.

The requirement is still deemed proper and is therefore made FINAL.

Art Unit: 1638

Claims 15, 17-40 and 44-48 are withdrawn from consideration as being drawn to non-elected inventions.

2. This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825.

Sequence identifiers are missing from the Brief Descriptions of Figures 4 and 5 and from pg 22, line 12, and pg 29, line 9.

Full compliance with the sequence rules is required in response to this Office action. A complete response to this Office action must include both compliance with the sequence rules and a response to the issues set forth herein. Failure to fully comply with both of these requirements in the time period set forth in this Office action will be held to be non-responsive.

3. The specification is objected to because there appears to be two Brief Descriptions of the Figures, one on pg 16-17 and the other on pg 17-19.

Claim Objections

4. Claims 2-4 are objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form. It is unclear in claim 1 what is intended to be claimed, a nucleic acid of SEQ ID NO:1 or a nucleic acid encoding an insecticidal complex or a fragment or homolog thereof, or a nucleic acid with 75% homology to SEQ ID NO:1. If what is intended is a nucleic acid of SEQ ID NO:1, then claims 2-4 are improperly dependent upon claim 1. A properly dependent claim includes all of the limitations of the parent claim(s), as well as a

Art Unit: 1638

further limitation. As SEQ ID NO:1 already comprises bases 1995-18937, 2411-9547, 9589-13883 and 14546-17467 of itself, the claim does not further limit the parent claim. If the intent is to claim a nucleic acid comprising only bases 1995-18937, 2411-9547, 9589-13883 or 14546-17467 of SEQ ID NO:1, then claims 2-4 are improperly dependent for failing to include all of the limitations of the parent claim.

5. Claim 10 is objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form. In addition to claim 1 being unclear, it is unclear in claim 10 what is intended to be claimed, a nucleic acid encoding an insecticidal complex or a fragment or homolog thereof and capable of hybridizing to the nucleic acid of claim 1, some other nucleic acid that hybridizes to that of SEQ ID NO:1, or a nucleic acid with 50% identity to the listed fragments of SEQ ID NO:1. A claim to a nucleic acid with a nucleic acid with 50% identity to the listed fragments of SEQ ID NO:1 is broader than a claim to a nucleic acid of SEQ ID NO:1 or a nucleic acid with 75% homology to SEQ ID NO:1.

6. Claims 14, 16 and 41 are objected to because of the following informalities:

In claim 14, there should be no comma after "including" in line 2, and there should be an "and" before pLAFR3 in line 4.

In claim 16, line 1, there is an improper article before "polypeptide".

In claim 41, line 2, there is an improper article before "nucleic".

Claim Rejections - 35 USC § 112

7. The following is a quotation of the first paragraph of 35 U.S.C. 112:

Art Unit: 1638

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

8. Claim 8 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter that was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Neither the instant specification nor the originally filed claims appear to provide support for the phrase "The purified and isolated nucleic acid of claim 1... *luminescens* toxins". The closest support is on pg 4, lines 1-8, in which the nucleic acid is operably linked to an additional nucleotide sequence, wherein that additional nucleotide sequence encodes the toxins. However, there is no support for SEQ ID NO:1, or any of its parts, being any of the listed toxins, as the current claims appear to state. Thus, such a phrase constitutes NEW MATTER. In response to this rejection, Applicant is required to point to support for the phrase or to cancel the new matter.

9. Claims 1, 9-14, 16 and 41 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter that was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The claims are broadly drawn to a multitude of nucleic acids that have 75% or 50% homology to SEQ ID NO:1. In contrast, the specification only describes a coding sequence from *Serratia entomophila* that comprises SEQ ID NO:1. Applicant does not describe other nucleic acids encompassed by the claims, and the structural and functional features that distinguish all such nucleic acids from other nucleic acids are not provided.

Art Unit: 1638

Hence, Applicant has not, in fact, described nucleic acids that have 75% or 50% homology to SEQ ID NO:1 within the full scope of the claims, and the specification fails to provide an adequate written description of the claimed invention.

Therefore, given the lack of written description in the specification with regard to the structural and functional characteristics of the claimed compositions, it is not clear that Applicant was in possession of the claimed genus at the time this application was filed.

See *Univ. of California v. Eli Lilly*, 119 F.3d 1559, 43 USPQ 2d 1398 (Fed. Cir. 1997) at pg 1406:

... A description of a genus of cDNAs may be achieved by means of a recitation of a representative number of cDNAs, defined by nucleotide sequence, falling within the scope of the genus or of a recitation of structural features common to the members of the genus, which features constitute a substantial portion of the genus.
... the claimed genera of vertebrate and mammal cDNA are not described by the general language of the '525 patent's written description supported only by the specific nucleotide sequence of rat insulin.

10. Claims 1, 9-14, 16 and 41 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a nucleic acid of SEQ ID NO:1, and a method of expressing SEQ ID NOs:2-4 in *E.coli*, does not reasonably provide enablement for nucleic acids that have 75% or 50% homology to SEQ ID NO:1, a recombinant expression vector comprising the nucleic acid, a method of producing the protein encoding by the nucleic acid and a plant, bacterium, virus or fungus transformed with the nucleic acid. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims.

The claims are broadly drawn to a nucleic acid that has 75% or 50% homology to SEQ ID NO:1, a recombinant expression vector comprising the nucleic acid, a method of producing the protein encoding by the nucleic acid and a plant, bacterium, virus or fungus transformed with the nucleic acid.

The instant specification, however, only provides guidance for determination that a 16.9 kb portion of pADAP has the ability to cause disease in *Costelytra zealandica* larvae (pg 23-25); sequencing of an almost 19 kb portion, SEQ ID NO:1, of pADAP to show that it has 9 ORFS, 3 of which, SEQ ID NOs: 2-4, have homology to protein components of insecticidal toxins of *Photorhabdus luminescents* (pg 26-29); expression of SEQ ID NOs:2-4 in *E. coli* and demonstration that they are active against grass grub but not other scarabs (pg 36-38).

The instant specification fails to provide guidance for a nucleic acid that has 75% or 50% homology to SEQ ID NO:1, a recombinant expression vector comprising the nucleic acid, a method of producing the protein encoding by the nucleic acid and a plant, bacterium, virus or fungus transformed with the nucleic acid.

The instant specification fails to provide guidance for exact hybridization or amplification conditions and probes/primers to use to isolate insecticidal protein-encoding nucleic acids that hybridize to SEQ ID NO:1, nor does it teach where to find such nucleic acids.

The instant specification fails to teach how to make insecticidal protein-encoding nucleic acids with 75% or 50% homology to SEQ ID NO:1.

Making substitutions in proteins does not produce predictable results. Lazar et al (1988, Mol. Cell. Biol. 8:1247-1252) showed that the “conservative” substitution of glutamic acid for aspartic acid at position 47 reduced biological function of transforming growth factor alpha while “nonconservative” substitutions with alanine or asparagine had no effect (abstract). Similarly, Hill et al (1998, Biochem. Biophys. Res. Comm. 244:573-577) teach that when three histidines that are maintained in ADP-glucose pyrophosphorylase across several species are substituted with the “nonconservative” amino acid glutamine, there is little effect on enzyme activity, while the substitution of one of those histidines with the “conservative” amino acid

Art Unit: 1638

arginine drastically reduced enzyme activity (see Table 1). All these mutated proteins, however, would have at least 95% identity to the original protein. The nucleic acids encoding all these mutated proteins, however, would hybridize under high stringency to the nucleic acids encoding the original protein.

Given the claim breadth, unpredictability, and lack of guidance as discussed above, undue experimentation would have been required by one skilled in the art to develop and evaluate nucleic acids encoding with 75% or 50% identity to SEQ ID NO:1. The insecticidal proteins encoded by SEQ ID NOs:2-4 are in total 4776 amino acids long. Making all possible single amino acid substitutions in an 4776 amino acid long protein would require making and analyzing 19^{4776} nucleic acids; these proteins would have 99% identity to any one of SEQ ID NOs:2-4. Nucleic acids with 75% or 50% identity to the 18937 nucleotide long SEQ ID NO:1, would have 4734 or 9468 substitutions, respectively; that is they could have substitutions in every amino acid in the protein.

The instant specification fails to provide guidance for which amino acids of SEQ ID NOs:2-4 can be altered and to which other amino acids, and which amino acids must not be changed, to maintain insecticidal activity of the encoded proteins. The specification also fails to provide guidance for which amino acids can be deleted and which regions of the protein can tolerate insertions and still produce a functional enzyme.

Guo et al (2004, Proc. Natl. Acad. Sci. USA 101: 9205-9210) teach that while proteins are fairly tolerant to mutations resulting in single amino acid changes, increasing the number of substitutions additively increases the probability that the protein will be inactivated (pg 9209, right column, paragraph 2). Thus, making and analyzing proteins with any number of amino acid substitutions that also have insecticidal activity would require undue experimentation.

Art Unit: 1638

As the specification does not describe the transformation of any plant with a nucleic acid that has 75% or 50% homology to SEQ ID NO:1, undue trial and error experimentation would be required to screen through the myriad of nucleic acids encompassed by the claims and plants transformed therewith, to identify those with resistance to *Costelytra zealandica* larvae, if such plants are even obtainable.

The claims are also drawn to nucleic acids that encode only one of SEQ ID NOs:2-4. The specification teaches that mutations in the coding regions for any one of SEQ ID NOs:2-4 eliminate the disease causing ability of all of SEQ ID NO:1 (pg 25, lines 11-14; Fig. 2c). Thus, none of SEQ ID NO:2-4 alone are sufficient to provide resistance to *Costelytra zealandica* larvae, and a plant transformed with a nucleic acid encoding only one or two would not be resistant. Additionally, nucleic acids encoding only SEQ ID NO:2 (SepA) could not be expressed in bacteria (Hurst et al, 2000, J. Bacteriol. 182:5127-5138; see paragraph spanning pg 5133-5134 and that spanning the columns on pg 5134). Furthermore, the specification does not teach how a use a nucleic acid encoding only one of SEQ ID NOs:2-4.

Given the claim breath, unpredictability in the art, undue experimentation, and lack of guidance in the specification as discussed above, the instant invention is not enabled throughout the full scope of the claims.

11. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Art Unit: 1638

12. Claims 1-14, 16 and 41-43 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter that Applicant regards as the invention. Dependent claims are included in all rejections.

Claim 1 is indefinite in its recitation of “nucleotide sequence of SEQ ID NO:1” followed by “that encodes at least one of ... hybridization conditions”. It is unclear which is intended to be claimed, a nucleic acid of SEQ ID NO:1 or a nucleic acid encoding an insecticidal complex or a fragment or homolog thereof, or a nucleic acid with 75% homology to SEQ ID NO:1. For purposes of examination, the claim was interpreted to read on all possibilities.

Claims 8 and 42-43 lack antecedent basis for the limitation “the *Bacillus ... luminescens* toxins”.

Claim 9 is indefinite in its recitation of “wherein the nucleic acid may comprise DNA, cDNA or RNA.” It is unclear what else the nucleic acid could be other than DNA, cDNA or RNA.

Claim 10 is indefinite as words appear to be missing between “molecules” and “said”, and between “thereof” and “capable” in line 2.

Claim 10 lacks antecedent basis for the limitation “the nucleic acid molecules” in line 2.

Claim 10 is indefinite in its recitation of “nucleic acid molecule as claimed in claim 1” followed by “wherein ... between the sequences”. It is unclear which is intended to be claimed, a nucleic acid encoding an insecticidal complex or a fragment or homolog thereof and capable of hybridizing to the nucleic acid of claim 1, some other nucleic acid that hybridizes to that of SEQ ID NO:1, or a nucleic acid with 50% identity to the listed fragments of SEQ ID NO:1. For purposes of examination, the claim was interpreted to read on all possibilities.

Art Unit: 1638

A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) is considered indefinite, since the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. Note the explanation given by the Board of Patent Appeals and Interferences in *Ex parte Wu*, 10 USPQ2d 2031, 2033 (Bd. Pat. App. & Inter. 1989), as to where broad language is followed by "such as" and then narrow language. The Board stated that this can render a claim indefinite by raising a question or doubt as to whether the feature introduced by such language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Note also, for example, the decisions of *Ex parte Steigewald*, 131 USPQ 74 (Bd. App. 1961); *Ex parte Hall*, 83 USPQ 38 (Bd. App. 1948); and *Ex parte Hasche*, 86 USPQ 481 (Bd. App. 1949). In the present instance, claim 10 recites the broad recitation 50% identity, and the claim also recites "preferably, 60%, more preferably 70% and most preferably 90-95% or greater identity" which is the narrower statement of the range/limitation.

Claim 14 recites the broad recitation "any suitable natural or artificial plasmid/vector", and the claim also recites "including, pUC 19 ... pLAFR3" which is the narrower statement of the range/limitation.

Claim 12 lacks antecedent basis for the limitation "The recombinant expression vector(s)" in line 1.

Claim 12 is indefinite in its claiming vectors and hosts. Claims should be drawn to only one product. If someone used only one, would be claim be infringed?

Claim 14 is indefinite in its recitation of references within the claim.

Claim 16 lacks antecedent basis for the limitation "said vector as defined above".

Claim Rejections - 35 USC § 102

13. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

14. Claims 1, 9-10, 12-14, 16 and 41 are rejected under 35 U.S.C. 102(e) as being anticipated by Kramer et al (US Patent 6,281,413, filed February 1998).

Kramer et al teach an isolated DNA encoding an insecticidal complex and with 54.0% identity to SEQ ID NO:1 (see search results). Kramer et al also teach recombinant expression vectors comprising the nucleic acid and plants transformed with it (claims 12 and 15-16) and a method of expressing the proteins encoded by the nucleic acid, wherein the method comprises transforming a host cells with a vector encoding the nucleic acid and recovering the protein (column 14, lines 29-61; column 19, lines 29-32; column 26, lines 20-53). The vectors are selected from any suitable natural or artificial plasmids or vectors.

15. Claims 1, 9-10 and 12-14 are rejected under 35 U.S.C. 102(b) as being anticipated by Jarrett et al (WO 98/08388).

Jarrett et al teach an isolated DNA encoding an insecticidal complex and with 53.1% identity to SEQ ID NO:1 (see search results). Jarrett et al also teach recombinant expression

Art Unit: 1638

vectors comprising the nucleic acid (claims 24-26). The vectors are selected from any suitable natural or artificial plasmids or vectors.

16. Claims 1-4, 7 and 9-11 are rejected under 35 U.S.C. 102(b) as being anticipated by Grkovic et al (1995, Appl. Environ. Microbiol. 61:2218-2223) taken with the evidence of the instant application.

Grkovic et al teach an isolated DNA, pADAP, from *Serratia entomophila* (Table 1). The instant specification teaches pADAP comprises SEQ ID NO:1 (pg 23-26 and Table 1). pADAP comprises bases 2411-9547, 9598-13884 or bases 14546-17476 of SEQ ID NO:1 operatively linked to additional nucleotide sequences that encode insecticidal proteins, that is the other insecticidal proteins encoded by SEQ ID NO:1.

17. Claims 5-6, 8 and 42-43 are free of the prior art, to the extent they read on a nucleic acid of SEQ ID NO:1 or bases 1995-18937 of SEQ ID NO:1 further comprising another sequence that encodes an insecticidal protein or bases 2411-9547, 9598-13884 or bases 14546-17476 of SEQ ID NO:1 operatively linked to nucleotide sequences that encode the insecticidal proteins listed in claim 8 (keeping in mind the objections and 35 USC 112, 2nd rejections above), given the failure of the prior art to teach or suggest an isolated nucleic acid of SEQ ID NO:1 or bases 1995-18937 of SEQ ID NO:1 further comprising another sequence that encodes an insecticidal protein.

Conclusion

18. No claim is allowed.

19. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anne R. Kubelik, whose telephone number is (571) 272-0801. The examiner can normally be reached Monday through Friday, 8:30 am - 5:00 pm.

Art Unit: 1638

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy Nelson, can be reached at (571) 272-0804. The central fax number for official correspondence is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Anne R. Kubelik, Ph.D.
February 2, 2005

A handwritten signature in black ink, appearing to read 'Anne R. Kubelik', is written diagonally across the lower right portion of the page.

PT animals - contains pesticidal material from *Xenorhabdus* species
PT optionally synergised with *Bacillus thuringiensis* toxin.

PS Claim 2; Fig 2; 46pp; English.

XX This is a toxin gene sequence cloned from a *Xenorhabdus* strain NCIMB 40887. This has insecticidal activity and can be used in an insecticidal composition for oral delivery to an insect. The composition includes material encoded by *Xenorhabdus* strains NCIMB 40886 and 40887, particularly it contains *Xenorhabdus* cells or culture supernatant. It may also include active materials from other sources, especially *Bacillus thuringiensis* or delta-endotoxins, and is formulated with a carrier, especially an edible material for the pest. Pesticidal agents isolated from *Xenorhabdus* species, especially *X. nematophilus* have oral activity against *Pieris brassicae* or rapae, *Plutella xylostella* and are heat-stable at 55 deg. C. They are resistant to proteolysis by trypsin and proteinase K, and are inactivated by sodium dodecylsulphate or acetone, and by heating to 80 deg. C. The compositions are used to kill Diptera and Lepidoptera, particularly *P. brassicae* or rapae, *P. xylostella* and *Culex quinquefasciatus*, e.g. for crop or animal protection, also for vector control. The isolated pesticidal agent may be expressed in transformed plants to impart protection. *Xenorhabdus* materials show synergistic effects when formulated with *Bacillus thuringiensis* toxins

XX Sequence 38258 BP; 10486 A; 8248 C; 8871 G; 10630 T; 0 U; 23 Other;

Query Match 8.8%; Score 1658.8; DB 2; Length 38258;

Best Local Similarity 53.1%; Pred. No. 0;
Matches 4978; Conservative 0; Mismatches 3802; Indels 596; Gaps 44;

QY	7301	ATGGACTTCTCCGGAGCCAAATGCCCTCTATTTCTGGAGCTGTCTATTACACGCCGATG	7360
DB	10859	ATGGATTTCAATAGTCCAGCGCCCTCTATTCTGGGA-ATGTTCTATTACCCCGATG	10917
QY	7361	ATGGTGTTCAGCGGTGTGTGAGAACAGCACTTCCCGAAGCCACCGCTGGTGCAG	7420
DB	10918	ATGTGCTTCAGCGTGTGTGTACAGGAAACAAATTCGACGAGCCACACAATGATATAC	10977
QY	7421	TATGTCGAGACCCGCGGCGAGTGTAAACGGGTGCTGCAGAAATACACCTGGAAT	7480
DB	10978	TAGCTCTATAATCCCGCGGTATATCGTTAACGGAGAAATCGCCCTCGATCTGGAAC	11037
QY	7481	GTCCGTCCGCTGAGGAGGACACCGCTGGAACGACTCGCGCTGGACTCCATTGACCC	7540
DB	11038	TGCGGCGCTGAGAG--ACACTCTGGAATGCCAATCCGTTGGATGCCATTGATCCG	11095
QY	7541	GATGCAATAGCCAGTACGACCCCATGCAATTAAGGTGCGCACTTTATGTGTAACCTC	7600
DB	11096	GATGCGCTGCACAAATGACCGGACACACTATAAAGTTGCCACCTTTATGCGCTGTTG	11155
QY	7601	GACCTGCTGATTCGCCCGGTGATGCGGCTACCGCTGCTGAGCGGACACCTTAAC	7660
DB	11156	GATCAACTTATTCGCGCGCGATATGGCCCTATTCGCGAACTGACCCGCGATGCTTGAAT	11215
QY	7661	GAGCGCCGATGTGTACGTCCAGGCGCTGAACCTTCTGGGCGACGACCTATATTTCC	7720
DB	11216	GAGCCCAAGATGTGTATGTGCGTGTGTGGAATTCCTGGGTGATGCGCGGAGGATTAAC	11275
QY	7721	TTTGACGCCGATGTGTGCGGTGTGACCTTGGGTGACGACGACGAGGTGACGCGACGC	7780
DB	11276	GGCAGCCAAACAGTGGGCGCACCGCTCTCTTCGTGGCGGCAACACACTGTGCAAGCG	11335
QY	7781	GATTACAGAGGCGCTGTGCGGCTGCGCGGTGTGGTCCCGCTCCCGAGACACGAGCG	7840
DB	11336	GGCTATCAACAAGACCTTACGCGGCTAGACACGAGAGGTTGCACTCAACCCCGCAAC	11395
QY	7841	GCGAATTCCTGACGCGCACTTCTCCCGCAGCAGAACGAGGTGCTCAAGGCTACTCG	7900
DB	11396	GCTAACTCTGTGTGG-TTTGGTCTCTGCCGGAATATAACCCGGAATCAACCGATTACTG	11454
QY	7901	CAAACTTGGCAGCGGCTCCATAACCTGCGGCAACAACTCTCCATTGACGCGCAGCG	7960
DB	11455	CAAAACC-TGCGTTTGGCGCTGTGTTACCTGCGGCAATATCTCTTCCA-TGACGGGCAACG	11512

QY	7961	CTTTCCCTGTCCGTCTACGCCACGCCCTCCGAAACCCGTCGCGCTGCAGAGTGCCTGCTC	8020
DB	11513	TTATCGCTGGCGAATTACGCGAGCC--TACGATCCGAAAGCGCTGCTCACAGTATGGTA	11570
QY	8021	AACAGCGCGCAGGTGTGACGACTCCGCGCGCGGTGATCGCGCTTACAGATTTCCCG	8080
DB	11571	CAGCCTTCTCAGGCGGTGTGTCAGTGTGCGCGGCAATTGTCTTATACCGCTTCCCG	11630
QY	8081	GTCTAGTGTGAGAACGCCCGGGGATGTGTAGCTGTGACCGGTTCGCGCAACACACTG	8140
DB	11631	GTGATGTGAGCGGCGCCGCAATCTGTGTAGCGCAATTACCCAGTTTCGCACTCTCTG	11690
QY	8141	CTCGGTATTACCGAGGTCTAGGATGCGGAGCGGTGCGCAAACTGTGTGACAGCCAGGC	8200
DB	11691	CTCAGTATGGCAGAGCATGATGTCGCGATGAACTCACCACTGCTACTACAGCAGGT	11750
QY	8201	AGTCACTGTATACGCCAGGCGCTTCGCGACGAGGATTAACGTCCTCGAGGAATCGATCG	8260
DB	11751	ATGGAATGGCGACACAGAGCATCCGTAATTGAGCAACGAACTGTGATGAAGTGGATGCT	11810
QY	8261	GATATTGCGCCCTGAGAGGAGCGCGCGCGCGAGATGCGTTTTTGAACGTTTACAAA	8320
DB	11811	GATATTGCTGTATTGGCAGAGAGCGCGCGCAGTGCACAAAATCGTCTGGAATAATACCAG	11870
QY	8321	GTGTTGTACGAGCGGAGCTCAACACCGCGCAAAACAGGCCATGGAATTTGATCTCAGT	8380
DB	11871	CAGCTGTATGACGAGGATATCAACACGAGGAGCAGCGTGCAGTGTCTACTGTTGATCGG	11930
QY	8381	TCGTCGCTGTCTCGGCATCAACCGCGCGCTCTTTTGGCGGAGCGCGCGCGATATG	8440
DB	11931	CGCGAGGTGATCTCTGCGCGCGGAGCGCTCTCAGTAGCAGAGGGGTGGCTGACTTAA	11990
QY	8441	CTGCCCAATATTTACGGGCTGCGCGTCCGCGCTCCGCTATGCGGCACTATTTAAAGCC	8500
DB	11991	GTTCAAACGTTTCGGTTTCGCTGTGCGCGAGTCTGTTGGGGGCGAGCTCGCTGCT	12050
QY	8501	ACCGCATTCGCATTCAGGTGTCTCCGATGCCACCGCATATCAGCGGACAAATACAGC	8560
DB	12051	TCGCGCTCGGTGTGCTCTTCTGCCACAGCTTCCCAATATTCGCGACAAATACAGC	12110
QY	8561	CAGTCGAAGTGTACCGCGCTCGCGGAGGAGTGGAAATCCAGCGTGTAGTTCGCGAG	8620
DB	12111	GTTCGGAAGCTTACCGCGCGCGCTCAGAGTGGGAAATTCAGTGATTAATGCTGAC	12170
QY	8621	TCTGATGCGCGCAGATTGATGCCAGCTGCGCGCATGGCAGTCCGCGGAGAGGCT	8680
DB	12171	GGTGAAGTCAACAAATGGATGCCAGCTGGAAGCTGAAATACGCGCGAGCAGCA	12230
QY	8681	GAGTCGAGAAAACCTTACCTTGAGACCCAGACCCAGGACAGGCGCAGTTGGCATTC	8740
DB	12231	CAGATGCAAGTGGAAATATCAGGAGACCCAGCAGGCCCCATCTCAGGCTCAGTTAGAGCTG	12290
QY	8741	CTGCAAGTAAAGTTCAACAATACGCTCTGTACAGCTGGCTGCGGGGAGGTTGTCGCC	8800
DB	12291	TTACAGCGTAATTCACAAACAAAGCGCTTACAGTTGGATGCGCGGCAAGCTGATGCT	12350
QY	8801	ATTTATTACAGTTCTATGACCTGCGCATATCCCGCTGCTGATGGCGCAACAGGCTGG	8860
DB	12351	ATCTATTACAGTTCTTTGACCTGACCCAGTCTTCTGCTGATGGCACAGGAGCGCTG	12410
QY	8861	CAGTGGGTAATTCGAGA---CTAGTGTGTTTATTCAGCCCGGGGCTCTGATGGGGGA	8917
DB	12411	CGCCGAGCTGACCCGACACCGGTGTTACCTTTATCCGCGGTGGGGCTTGGAAACGCTACG	12470
QY	8918	AATCGCGCTGCTGGCGGGGAAACCTGATGCTGTAATCTGGCGCAGATGGAGCAGGCC	8977
DB	12471	ACTCGCGGTGTGATGGCGGGGTGAACGTTGCTGCTGAATCTGGCAGAAATGAAAAGTC	12530
QY	8978	TGGCTGACGCGGGGATGAGCGGCAATAGAGGTGACGCGGAGGCTGCTGCTGTCGAGGTC	9037
DB	12531	TGGCTGAGCGGTGATGAGCGGCACTGGAAGTGACCCGCTACCGTCTGTTGGCACAGTTC	12590

14745 TTACGGCTTATCGGCGCCAAATAGTGTACTCGTCTGGTCAAAATAATCCGGCAGGATGGGAT 14804
11218 AAAGGGAGACCGGTGCAGCAAAACGAAAGACTCACTCTGCGGTCCGGGGGTGTGACCCA 11277
14805 CGCGCTCAGGATGTATTCTTTGTCAAATAAGCCACTCGCGGTTCCTCCGCGCAAAATAAG 14864
11278 CGTACCCCTCGTGGCGTTTCAGTGATATGGCTGGCAGTGGACAGCAGCATTTTGAACGAGGTG 11337
14865 CGTCATCTTGTGCAATTCAGTGATATGACAGGCTCCCGGGCAATCACAATCTGCTGGAAGTT 14924
11338 CGTGCTAATCGAGTACGTTACTGGCCAAACCTGGGCAACGCTGCTTAAACCTGACCAGATATTGCTGGCC 11397
14925 ACGGCAAAATACGCTGCGCTACTGCGCAACCTGGGCAATCGAAATTTGCTGAGCCCTCTG 14984
11398 AATATTCCCGGTTTATAGCCAGTCAGTGACTACGTTTAAACCTTACCAGATATTGCTGGCC 11457
14985 ATGATAACAGG-CTTCCAAATTAACGGGGAACGTTTAAACCCACAGACTGATATATGGTA 15043
11458 GATACCGAGGTTTCCGGTACCA-CGGACCTGATTATATGCAATGAGTGAACGGTTAGTCAAT 11516
15044 GACCTAAATGGCTCAGGCAACCCCGATTTTATTTATGCGCGCAATCTTACCTTGAACCT 15103
11517 TTATTTCAACAGAGTGGTAATTTATTTCCGCGAGCGGCATACGCTGCTCTTGCCTGCAAGG 11576
15104 CTATGCCAATGAAGCGGCAATCTCTGCTGAACTCAGCTTGAATTTGATCTCCCGATGG 15163
11577 TGTGGCTATGATCGCACTGCGAGTCTGCAAGTGGCGATATCCAGGGCTCGGGGTGCC 11636
15164 GGTACGTTTGTGATGATCTTGTGCGTTACAAATAGCGGATACACAAGATATAGGACTGCG 15223
11637 TAGCCTGTTACTGACGCTCCCGCATGTGCGGCTCATCACTGGGTGTGCAATTTATCGCG 11696
15224 CAGCATTAATTTGACGATCCCGCATATGAGGTGCGACACTGGCGATTGGATATGACCAT 15283
11697 AGACAAACCTCGTTTGTGAAATGGCATGAACAAACAATATGGGGCCCGGCATGCACTGCA 11756
15284 ATTCAGGCTTGGCTGCTGTAATGCGTCAATAACAATATGGGAACAGAAACCAAGCTGTA 15343
11757 CTATCGCAGTTTGGTGTGAGTTCTGCTGGATGAGAAAGCCAGGCACTGGCGGACGAGCAG 11816
15344 TTATCGCAGCTCTCCCGAGTTCTGGCTGATGAGAAATACAGGCTTCTGAATCCGGGAT 15403
11817 TTCCCTTGCCTGCTACCTGCCATTTACATTCGATACCGTGTGGGTTCGGTGTGCAAGTA 11876
15404 GACGCTGCTCAGCTACTTACCGTTCCGGGTGATGTGTGGCGCACGAAAGTCTGGA 15463
11877 TGAGATCACCGGTAAACGCTGTGTCAGCAGCTCTTTATGCGCACCGGCTGTGGGACGG 11936
15464 TGAAATTTCCGGTAACCGATTGACCAGCATTAATCATTTACTCAATGCTGCTGGGATGG 15523
11937 GCAGGAACCGGAGTTTCGGGGTTTGGTTTGTGTGATCAGGAGTACCGATACCTTGAATTCACGGGC 15583
15524 TCTGGAAACGGGAGTTTCGTGTTTTCGGCGGTGACGCAAACTGATATTGAATTTGGA 12050
11997 AAG-----CCAGGTACGGCGACGGAACCTGAGTATGCTTCTGTAGCCGGAACCTGGA 12584
15584 GAGTGCACACAGGGGACACATGCTGAACCAACCGGACCTTCCGGCAGGTTAATTTGGA 15643
12051 TGCAACCGGGTACCGGAGTACAGAGCGTCTGCGGAGACGATATTGGCAAAACGATGC 12110
15644 CGGCATCGCGTACGGGAAGTGGATATCTTCTGCGCCACGGAATATTGGCAGGGGATCA 15703
12111 CGCCGCTTTTGGCGATTTCCGGACCCGTTTTCAC-----TGTGCGTTTCAGGAGAGATGA 12164
15704 ACAGGCAATTTCCCAATTTATCCCAACGCTTTTACCGGTTATGACAAAAATCCGGTGTGA 15763
12165 GCAGACATATATCCGGACGACAGCAAGACATTTCTGTTGACGAGCGCTGAAAGGCAAT 12224
15764 TATGACGCTCAGCGGACGGAACGGAAGAACTTGTTTACATCAGCGCTTAAAGGACA 15823
12225 CCTGCTGCGCAGTGAATTATACGTTGCCGATGGCAGCAGCGGCGGATATCCCTTACAG 12284
15824 ACGTTTACGCACTGAGCTGTATGGGGATGATGATTTCTATCTGCGCGGTACGCTATTTC 15883

QY	12285	CGTCACTAGTCTCGCCCGCAGGTACGCTAGTTTGAAGCGNATGGA---GACTACCCGGT	12341
Db	15884	AGTGGATGAATCCCGCACCCNAGTACGTTTGTACCGGTGATGTATCGGACGTGCCTGC	15943
QY	12342	GGTGTGCCGATGGCGCGGAAAGCCGTACGTCAGTTTATGAAACGGTACCCACAATGA--TC	12400
Db	15944	GGTACTGGTTTCGGTGGCGGAATCCCGCAATACCGGATATGAAGGGTGTGTACCGATT	16003
QY	12401	CTCAATGCCAACAGCAGCGCGTACTCTCTAGTGAATACGGTTTCCCATCTCGTCCAGG	12460
Db	16004	CACAGTCACCCAAAGATTGTCCTTAAATATGATGCTGTAGGATTTCCGAGGACAATC	16063
QY	12461	TCAGTGTCAATATCCACAGCGCCCTCCGTCGGCGGACAATCATATCCGGCTCGGTTAC	12520
Db	16064	TTGAGATTGCTATTCCAGAGCTCCACAGCCTGAGTTCTCGCTTATCCGGATACCCCTGC	16123
QY	12521	CGCGCAGCTGTTTCGCAACAGTTATGACGAGCAGCAGATATTTACGCTCGGGTTGC	12580
Db	16124	CCGAAACACTTTTACCCAGCAGTTTCGAGCAACAGCAGATGTTCTCTTCGTCT---GACAC	16180
QY	12581	AACAGAGCAGTGCACATCACTTGTCTTCTACTCTCTGAGGGCATTGGTTGTGGGGTTGG	12640
Db	16181	GCCAGCGTTTCTTATCACTTGAATCATGATGATTAATACGTGATCAAGGGCTTA	16240
QY	12641	CGGAGCGTCTGGGAGCAGATGATTTCAAGTACTCTGCGGACAACGTGCCGAAGGGGTC	12700
Db	16241	TGGATACCTTCACGCACTGACGACGATTTATCAAGCCGATTAAGTCCCGGACGTGGAT	16300
QY	12701	TGACGCTGNAACACTGTTGGCGCCGAAAGCCCTGGTCTCGGATAGTCAGGTCGATACGC	12760
Db	16301	TTTCCCTTGAATGGTTTCTGCTG-----CACAGGTGCAGGACATTGTTGTCCTCG	16351
QY	12761	TGGCGGGTCAGCAGCAAGTCTGGTATCTGGATTACAGAGCGTTCACAGCGTCGCTGTC	12820
Db	16352	ATGCCCGCAGCGATTATCTGGGACATCAGCGTGTAGCATATACCGGTCCAGAAGACAA	16411
QY	12821	CGCCACTCCCCCCCAGGTAGCTTTTATCGAAACGGCGCTGCTGATGAGGTATGTCATC	12880
Db	16412	CGCTATTTCTCCGCTGGTGTGCATACATTTGAACCGCAGAGTTTGTATGAACGATCGTTGG	16471
QY	12881	GTTCACTGGCTGCCTACATTCTGGA-----TGAACATCTCAGCAAGCCGGTTACCG	12932
Db	16472	CGGCTTTTGAGAGGTGATGATGAGCAGGAGCTGCACAAACAGCTGAATGATCGGGCT	16531
QY	12933	GCATTCGGATACCTTTTCCCTCGAGCAGGGAAGCAGAAACAGGCAATGTGGACCCAGTG	12992
Db	16532	GGAAATCGGCAAAAGTCCGCTTCACTGAAAGA--CAGATTTCAATGTCTGGGTGGGACA	16589
QY	12993	TCAGGATATGTTACCTATATCGCGCGCAGAGCATTTCTGGCTACCGCTATCTTTTCGGGA	13052
Db	16590	AAAGGAATTCAGAAATATGTCGGGTGAGACGGATTCTATCGGCCATTGGTGCACCGGA	16649
QY	13053	CAGTATGTTTACCGCGCCAGATTACCGTGAACGCTGACGGTACGACTGGCTCATCACGCA	13112
Db	16650	AACCAAGCTTACAGTTCACAGCAGTGAAGTGGGATAGCCATTACTGTGTTATCACCGC	16709
QY	13113	GTGGCAGGATGCGCAGGATTTGTCAACACAGCCGACTATGCTGCGGCTTCTCTGACGCC	13172
Db	16710	AAACAGGATGCGGCTGGCTTGGTATGCAAGGCAATACGATTATCGATTTATGTTTGC	16769
QY	13173	CGTCCGGGTGACGGACCCCAATGATTAATCTGAGTCCGTCCTCTGGATGCTCTGGCCG	13232
Db	16770	GGATAACCAACAGATATCAATGATAACTATCACACCGTGACGTTTGATGCACTGGGAC	16829
QY	13233	GGTGACCACTCTGGATTCTGGGGCAGCAGAGATGGTATGCGCACCGGTTACAGTGAATGC	13292
Db	16830	GGTAACCACTTCGGTTTCTGGGGAGCTGAAACCGTGAACAGGATATACCCCTGC	16889
QY	13293	CAGTTGTCCGTTCCGAGCGCGCAGCAGCCGCTCTGGCGTTGACGGCGCCCTTACCACT	13352
Db	16890	G-----GAAATGAACACTGCTCCCTTTATGTTCCCAACACCGGT	16928

16651 AGAAATTTTACAAACCTGCTTATGATATGATCTCTCGGAAATGCTGAAATCAA 18710
 15546 ATACGATCGGAGACACCGCTTCTGCGGTAAACAGAAAGTGTACCGGAGATACGT 15605
 18711 CTAATGATGCTGAAATTAACCGCTTTTGGCGCAACAGAAATTTGACCGGAAATACTT 18770
 15606 ACATCTACGACGCTGTACGAGTGTGTGACGCGCACAGGCGGTGAGATGCCAATGCGG 15665
 18771 ACACCTATGACAGCGCTGTACAGAGTGTGTTCCGTCACTGGCGGTGAATGGCGATATTG 18830
 15666 GCCAGCAGGCGCAACGACTTACCATCCGTACAGCGCCCTTCTTACAGACAGCTCTGCT 15725
 18831 GCCGCAAAAACACGTTAC-----CCATCCCGCTCTGATTGATAACAATACTT 18881
 15726 ACACCAATTACACGCGACCTACCGTTATGACCGTGTGTGGCAACTGACGAGATGGCC 15785
 18882 ATACGAATTACTCTCGCACTTACGACTATGATCTGTGGGGAATCTGACCAAGATTCGATA 18941
 15786 ACAGTGGCCCTGCCAGCAACAATTAATACGACAGACATCACCGTTAGTGACCGCAGCA 15845
 18942 A-----TTCAGCATCACCGGTAAATACTATACACGAACATGACCGTTTCAGATCACAGCA 18997
 15846 ATAGGCGGTACTGACGACGCTTGGCGGAGTGGCGTCAAGTGTGATGTTGATGTTCACTG 15905
 18998 ACCGGCTGTACTGAAAGAGCTGGCGCAAGATCCCACTCAAGTGGATATGTTGTTACCC 19057
 15906 CAGAGGTACACAGAACCTCTGACGCGCGGCGCAAGCACTGCTGACGCCACGCTGGAG 15965
 19058 CCGCGCGCATCACACCGCTTGTCCCGTCAAGATCTTTCTTGACACCCCGGTGACG 19117
 15966 AACTGCAAAAGTGACACCGGTGTGTGATGGGGGGCGGACGACAGCGAAAGTATC 16025
 19118 AATTGCAACAAGTGATATTGTTCAATAGGGAATAACGACGCTGTACGAAATTTTACC 19177
 16026 GGTATGATCGGCGAGTCAAGTATTAATCAAAACCGGCGACGCGCAAACTGGCAACAG 16085
 19178 GTTATGATGACAGACGCTGCTGCTTAAAGACTCATATTCAGAAAGAGGTAACAGTG 19237
 16086 TTCAGACACGCGGTAGTGTACTGCGCGGCTGGAGTTACGTATCATGCGCAATGGCG 16145
 19238 AGCAATACAGCGAACAATTATTTGCGAGAGCTGGAATGGCGCACGACATATAGCGGCA 19297
 16146 TGACGGAAGAAAGCTGACGTTATTAACGTTGGCGGAGGCTGGCGGCGCACAGTGC 16205
 19298 ATACATTAAGAGTTTGTGAGGTCTATCACTGCTGCTGAGCGGTGAGGACAGTGC 19357
 16206 GCGTTATGCACTGGAGATCGGACGCGGATGACCTCGATGAGGACTCGGTGCGTTACA 16265
 19358 GGTGCTGCAATTGGGAAACAGGGCAACCGCGGATATCAGCAATGATCAGCTGCGCTACA 19417
 16266 GTTACGATAACCTGTGGCGAGCAGCAGCTGAGCT-CGACAGAGAGGTTACCTTATC 16324
 19418 GTTATGGCAACCTGATTGGCAGTATGGCGGTGGAATTTGGGACAGTGAAGGAGATCAT 19477
 16325 AGTGAGGAGGTTTACCCGTATGCGGAACGGCTGTTCTGACGCGCGGAAGTCAAGTT 16384
 19478 AGTCAGGAAGATTAATACCCCTATGCGGGAACCGCG- TGTGGGCAACCGGAATCAGTCA 19536
 16385 GAGGCTGACTACAAACTATCCGATCTACGCAAGAGAGCGTGAACGCGGCGCTGGAT 16444
 19537 GAAGCTGATTACAAAGCGCGGTATTCTGCAAGAGAGCGGATGCAACAGGTTGTAT 19596
 16445 TATTACGGTTATCGGTATTACAGCCATGGGCGGCTGGCTCTCCACGACCCCGCA 16504
 19597 TACTACGGCTATCGTTATTAATCGTGGACAGGCGGATGTTGAGTGTAGATCCTGCC 19656
 16505 GSCAGGTGGAGCGGCTGAACCTGTTCCGATGTTGCGGAATAATCCCGTCAACGCTGTT 16564
 19657 GGTGAGCGCGATGGTCTCAATTTGTTCCGATGTCCAGGATTAACCCCATCGTTTCT 19716
 16565 GACACCAACGGCGGATC 16582
 19717 GATTCGATGGTGGTTC 19734

RESULT 7
 AAV17876/c

ID AAV17876 standard; DNA; 38258 BP.

XX AAV17876;

XX 23-JUL-1998 (first entry)

Cloned toxin gene sequence from *Xenorhabdus* strain NCIMB 40887.

Xenorhabdus; toxin; insecticidal; protection; *Pieris brassicae*; crop;
Pieris rapae; *Plutella xylostella*; *Lepidoptera*; *Diptera*; animal; ss.
Xenorhabdus sp.

W09808388-AL.

XX 05-MAR-1998.

XX 27-AUG-1997; 97W0-GB002284.

XX 29-AUG-1996; 96GB-00018083.

(UKAG-) UK MIN AGRIC FISHERIES & FOOD.

XX Jarrett P, Ellis DJ, Morgan JAW;

XX WPI; 1998-179074/16.

XX

Orally active insecticidal composition, used for protection of crops or animals - contains pesticidal material from *Xenorhabdus* species optionally synergised with *Bacillus thuringiensis* toxin.

XX Claim 2; Fig 2; 46pp; English.

CC This is a toxin gene sequence cloned from a *Xenorhabdus* strain NCIMB 40887. This has insecticidal activity and can be used in an insecticidal composition for oral delivery to an insect. The composition includes material encoded by *Xenorhabdus* strains NCIMB 40886 and 40887, particularly it contains *Xenorhabdus* cells or culture supernatant. It may also include active materials from other sources, especially *Bacillus thuringiensis* or delta-endotoxins, and is formulated with a carrier, especially an edible material for the pest. Pesticidal agents isolated from *Xenorhabdus* species, especially *X. nematophilus* have oral activity against *Pieris brassicae* or rapae, *Plutella xylostella* and are heat-stable at 55 deg. C. They are resistant to proteolysis by trypsin and proteinase K, and are inactivated by sodium dodecylsulphate or acetone, and by heating to 80 deg. C. The compositions are used to kill *Diptera* and *Lepidoptera*, particularly *P. brassicae* or rapae, *P. xylostella* and *Culex quinquefasciatus*, e.g. for crop or animal protection, also for vector control. The isolated pesticidal agent may be expressed in transformed plants to impart protection. *Xenorhabdus* materials show synergistic effects when formulated with *Bacillus thuringiensis* toxins

Sequence 38258 BP; 10486 A; 8248 C; 8871 G; 10630 T; 0 U; 23 Other;

Query Match

Best Local Similarity 6.7%; Score 1260.8; DB 2; Length 38258;
 Mismatches 3921; Conservative 0; Mismatches 3082; Indels 541; Gaps 27;

Qy	2511	TGACGGATTATTTCTCGCTTCTTCCCGAGGTCAAAAATCACTGGCAGACGCTGT	2570
Db	28349	TGACAAACATTCGTTATGTCCTTCAGCGAATTTGTCATAGCAAGTGAACCTGA	28290
Qy	2571	CATGGGAGAGGTCTGTATCTCTACAGTCAGCGCGACGACGACAGAAAGAAACGGC	2630
Db	28289	CGTGGCGAGAAACAGACTTTTATATCAACAGGCTCATCAGGAATCAAAACAGATAAC	28230
Qy	2631	TCACCGAATCCCGTATTTCTGGCCCGGCGGAATCCCTACTGTTGATGCGTTCGCTGG	2690
Db	28229	TTGAAGAACTGCGCAATTTTGTCCCGTGTCTAATCCAACTGGCTATATCACTAACCTTA	28170

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: January 26, 2005, 06:14:03 ; Search time 1470 Seconds
(without alignments)
9156.605 Million cell updates/sec

Title: US-10-070-489A-1
Perfect score: 18937
Sequence: 1 99atccgagtgaagaaatca.....cgtgccagcgagcatggc 18937

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 824507 seqs, 355394441 residues

Total number of hits satisfying chosen parameters: 1649014

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents NA: *
1: /cgn2_6/ptodata/1/ina/5A_COMB.seq: *
2: /cgn2_6/ptodata/1/ina/5B_COMB.seq: *
3: /cgn2_6/ptodata/1/ina/6A_COMB.seq: *
4: /cgn2_6/ptodata/1/ina/6B_COMB.seq: *
5: /cgn2_6/ptodata/1/ina/PCTUS_COMB.seq: *
6: /cgn2_6/ptodata/1/ina/backfiles1.seq: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	2368.8	12.5	37948	3	US-09-251-645-11
2	1108.8	5.9	4431	4	US-09-817-514A-3
3	969.8	5.1	4458	4	US-08-851-567B-31
4	903.4	4.8	6055	4	US-08-851-567B-25
5	848.8	4.5	7551	4	US-08-851-567B-46
6	848.8	4.5	7551	4	US-09-637-048C-1
7	848.8	4.5	7551	4	US-09-817-514A-1
8	848.8	4.5	7551	4	US-10-435-835-1
9	815.2	4.3	7577	4	US-09-637-048C-3
10	815.2	4.3	7577	4	US-10-435-835-3
11	815.2	4.3	7621	4	US-09-637-048C-6
12	815.2	4.3	7621	4	US-10-435-835-6
13	781.2	4.1	7512	4	US-09-817-514A-7
14	781.2	4.1	7515	4	US-08-851-567B-11
15	781.2	4.1	7515	4	US-09-637-048C-2
16	781.2	4.1	7515	4	US-10-435-835-2
17	748.6	4.0	7541	4	US-09-637-048C-4
18	748.6	4.0	7541	4	US-10-435-835-4
19	725	3.8	3132	4	US-08-851-567B-60
20	629.4	3.3	2745	4	US-09-817-514A-5
21	608.2	3.2	1740	4	US-08-851-567B-50
22	579.4	3.1	1722	4	US-08-851-567B-54
23	439.2	2.3	5547	4	US-08-851-567B-48
24	388	2.0	5532	4	US-08-851-567B-52
25	277.4	1.5	2557	4	US-08-851-567B-36
26	260	1.4	4832	4	US-08-851-567B-58
27	173.4	0.9	1889	4	US-08-851-567B-29

ALIGNMENTS

RESULT 1

US-09-251-645-11
; Sequence 11, Application US/09251645
; Patent No. 6281413
; GENERAL INFORMATION:
; APPLICANT: Kramer, Vance C.
; APPLICANT: Morgan, Michael K.
; APPLICANT: Anderson, Arne R.
; APPLICANT: Hart, Hope
; APPLICANT: Warren, Gregory W.
; APPLICANT: Dunn, Martha
; APPLICANT: Chen, Jeng S.
; TITLE OF INVENTION: NOVEL INSECTICIDAL TOXINS FROM PHOTORHABDUS LUMINESCENS
; FILE REFERENCE: AND NUCLEIC ACID SEQUENCES CODING THEREFOR
; CURRENT APPLICATION NUMBER: US/09/251.645
; CURRENT FILING DATE: 1999-02-17
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 11
; LENGTH: 37948
; TYPE: DNA
; ORGANISM: Photorhabdus luminescens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (15171)..(18035)
; OTHER INFORMATION: orf5
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (23768)..(31336)
; OTHER INFORMATION: hph2
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (31393)..(35838)
; OTHER INFORMATION: orf2
US-09-251-645-11

Query Match 12.5%; Score 2368.8; DB 3; Length 37948;
Best Local Similarity 54.0%; Pred. No. 0;
Matches 6358; Conservative 0; Mismatches 4747; Indels 671; Gaps 47;

Oy	5291	CGCATACCTTCCTCGGGTATCTCTGCTGATATCAGGTGTCAGGTCAGGCAAGGTAAACCC	5350
Db	5569	CGTGATGATCTATATCAATACCTATTGATCGATAACCAAGTTTCGCGCGCATTTAAACT	5628
Oy	5351	ACCCGCATTGCGGAGGCATCGCGGCATACGGCTGTATATCAACCGGCCCTTAAACCGA	5410
Db	5629	ACAGAGATCGTGAAGCTATCGGTAGTATCAACTGATATTAACCGCGGCTTGAANAAT	5688
Oy	5411	ATAGAATCAGCGCCATCGGAGAGGTGAGGGGGCGTCAGTTTTTCACTGACTGGGATACG	5470

10058 CGGGCCGATGGGATGGCCGCGTGTCTCTGCGGTTGCCATCTCTGCGGGCGCGGTTA 10117
 9750 CGCCCCACATGGGGCACTTAATATATACAGCCGGTGGGGAACGGCCCTTTTGGCAATGG 9809
 10118 TGCTCCGTACTCGCCTTAACTACAAACGCGCGGTAAACAGCCCAATTTGGTCTGG 10177
 9810 CTGGGTATCGCGGTGCTGCTCTCAGCGTCTGTAACGCGAACGGAGCACTTACCTACGA 9869
 10178 CTGGGATGCAACGTTATGACCAATCCGCCGCCACCCCAATTTTGGCGTTCCCAATATGA 10237
 9870 TGATCTGATGAATTCACCGGTCCGACGCTGAGGTGCTGCTGCTCGCGCACTCACGCTGC 9929
 10238 TGAACCGATACCTTTCTGGGGCAGATGCGAGGTACTGGT----- 10280
 9930 TGGACCCAAAGAACGCGAGGCCACTCACTACTGGGGATAAACCCAGCGGAAGCTT 9989
 10281 -GTAGCGGATCAATCCCGGACGAAATCGAATACAGGGTATCAACTTAGGCACCGCCTT 10339
 9990 CAACGTTTACGTTTACCGTTTACGTAACGAGGAGGTCTCAGCGGCTTGGAGTTGGCT 10049
 10340 TACCGTTTACCGGATACCGTTTCCCGTCTGGAGAGTCAATTCAGCCGATTTGGAATATTGGCA 10399
 10050 GCCCGCGACGAGACAG-----AAACGGAATTTTGGGTGTATATACCCTGA 10097
 10400 ACCAAGCAACACCAAGACNACTGGCAAAACGATTTTGGCTGATATATAGCCAGA 10459
 10098 CGGACAGGTGCTCTGTGGCGGAATGCGAGGCTCGCATCAGCAACCCCAAGCCCC 10157
 10460 TGGCAAGTACATTTACTGGGTAAATCACCACAGCCCGATCAGCAACCCGTGAGCAT 10519
 10158 AACACAGCGCGTTTGGCTGATGAGTCTCTGGTATCACTTACCGCGCAACAGATGTA 10217
 10520 CACTCAACAGCAACAATGGTTGTAGAGGCTCTGTCTACCAATGGTGAACAAATTTA 10579
 10218 TTACCAATACCGTCCGGAAGATGATGCGTTTGTACGAGCGGAGCGGACGCGACCC 10277
 10580 TTATCAATATCGGCGGAGGATAACCGGTTGCGAAGCTGATGAATTTACTCTCAATCC 10639
 10278 GCAGCGCGGCCCAAGCTTATCCGTTGCGGTGCGGTCTGATGTTAAACCGTCAGCGCGCTG 10337
 10640 ACAGCGCGCGCAAGCTTATCTACACACAGTGTATTAACGGCAACCGGACAGCAGCAA 10699
 10338 GACCTACCGCGCTGTGTGCGA---CACCATCAATGATAGTCTGCTGTTTATCTGCT 10394
 10700 AACGTTTACCGCGCTGATGCGCGGCCCAACCAAGCAGACTGGTTATTTCTATCTGGT 10759
 10395 GTTTGATTTAGTGAGCGTAGCTCGGTGCTCTGTAAGCGCGCGCTGGCAACACCCAGG 10454
 10760 ATTTGATTTACGGCAACGCACTAACACCTGAGAACCGCGCCAGCATTTTCGACTACAGG 10819
 10455 AAGTGGGAGTGGCTGTGCTCAGGATTTTTCGGGATGATGATTTGGTTTAACTTAACT 10514
 10820 TAGC-----TGGCTTTTCCCGCAGGACCGTTTTCCTCGTTATGAATATGTTTGGAT 10873
 10515 GCGGACTCGCGCTGTGCGCTGAGTTTTCATGCTTCCATTTACCTAGTGTCTGCGCGG 10574
 10874 TCGTACCGCGCGCTTATGCGGTGAGGTATGATGATCACCACCTGCAAGCTCTGGATAG 10933
 10575 GAGTTTCGGGAGCAATGATGCGCCAGCATTTGATTTCTCGCTGTTGCTGACTACAGGGA 10634
 10934 CGAGATAAAGAACACACAGGACCAACGCTGTTTTCAGCTGATCTCAATATATGACA 10993
 10635 AAGTCTTCACTGCTGCTGAGAACGTCGACAGGTGCTTATGATGCGGACCGGAC 10694
 10994 AAGCGCAATCGCAGCAGCTGGTATTCGTTCTGAGTAGGCCACAGCAAGACGCTAC 11053
 10695 GTCTTGTCTTTCGCGCACTGGCAATTCGGGTGCAACCTTTTACCGCGCGCATTTGTC 10754
 11054 TGGCTGACCTTGGCGCCATTTAGAAATTCGGGTATCAGGATTTTTCACCGCAACATACGC 11113
 10755 GGCATGGCAGACGCTGACGATATGGGAAGTTGAGTTTGTCTCAACCCCTATCAGCTTGT 10814

11114 TCGTGGCAATCGATGAATGTGCTGGCAAACTTCAATGCCATTGAGCGCTGGCAACTAGT 11173
 10815 AGACCTTAACCGCGAAGGTGTGGGTATCTGTATACGACAGCGGTGCTCTGGTGGTA 10874
 11174 TGATCTAAAGCGCAAGGATTTCCCGGTCTGCTATATCAAGATAAAGCGCTCTGGTGGTA 11233
 10875 CCGTGAACCGGTAGCCAGTGGGGGATGATCCCGATGCTGTGACCTTGGGGGGCGGCTGC 10934
 11234 CCGTCCGCAACAGCTTTTGGCAAAATTTGGCTCAGATGCGCTCACTTGGGAAAAAATGCA 11293
 10935 GCGCTCGCGCAAAATGCGCGCTTTGCATAAACAGCGGCATCTTGGCGGATCTTAATGGGGA 10994
 11294 ACCTTTGTCGGTATCCCTTCTTGCAAAGTAAATGCTCTGCTGGTGGATATCAATGGAGA 11353
 10995 TGGTGGCTGAGTGGGTGCTTACCGCCCCCGGTGTGGCGGGATGATATGATCGCACCCC 11054
 11354 CGGCAACCTTGAATGGGTATACCGGACCGGATTTAGCGGATATCATAGTCAGCATCC 11413
 11055 CGGCGCGACCTGTTGCAATTTACCCCCCTGTACGCTTGGCGGTAGATATGGCATCC 11114
 11414 AGATGGCAGTTGGACACGTTTTTACCCCCCTCAACGCTCTGCCAGTGGAAATATCTATCC 11473
 11115 AAAACAGTGTGCGCGGATATCTGGGGCTGGGTTAAACGACATGCTGCTTATCGGCGC 11174
 11474 ACGCGCGCAACTCGCGGATTTAAATGGAGCTGGACTTTCTGATTTAGTACTGATCGGCGC 11533
 11175 GCGAGTGTGCGCTCTATTCGCGCAAAAACATGTTGGTAATAAAGGGAGACCGTGCA 11234
 11534 TAAGAGTGTACGTTTATATGCAATACCGCGACCGCTTTGCAAGGAAAGATGTAGT 11593
 11235 GCACAGGAAAGACCTCACTCTGCGGCTCCCGGGTTGACCCACGATCCCTGCTGCGCGCT 11294
 11594 GCATTCGGTGTATACACTGCCAGTACCGGCGCGGCTTCGTTGATGTTGGCTGCTAT 11653
 11295 CAGTGTATGCTGGCAGTGGACAGCAGCATTTTGAACGAGGTGCTGCTTAATGGAGTAGC 11354
 11654 TAGTGTATGTTGGGTTCCGGTACGACACATCTGGTTGAGTGAAGCGGACTAAAGTCA 11713
 11355 TTACTGGCCAAACCTTGGGCGACGCTGTTTGGTTCAGCGGTGAAATATTCGCGGTTTTAG 11414
 11714 CTGCTGGCTTAATCTGGGCGACGAGCTTTTGGTCAACCAATTTACTCTTCCGGGATTTAG 11773
 11415 CAGTCACTGCTGCTGCTGACAGATTTTGTGGCGGATATCGTGGCGGATCCGACGCTTCCG 11474
 11774 CCACAGAGAGCAGCTTTTATCTCTCAAGTTTATCTGGCGGATCTAGATGGCAGCG 11833
 11475 TACCACGACCTGATTTATGCGATGAGTGAACGCTTGTAGTCAATTTATTTCAACACAGAGT 11534
 11834 CCGGCTGATCTGATTTATTTTCAACAGATCGTCTGGATATCTTCTGAAATAAAGCGG 11893
 11535 TAATTTATTTGGCGGACCGCATACGCTGCTCTTGGCGAAGGTGCGCTATGATCGCAAC 11594
 11894 CAACGCTTTCGCGCACCAAGTAACTCTCCCTTCCAGCGGAGTGGCTTTTGTGATCATAC 11953
 11595 CTGAGTCTGCAAGTGGGGATATCCAGGGGTGGGGGTGCTGCTGCTGCTTACTGACGCT 11654
 11954 CTGCTAGTTACAGTGGCGGATGTAAGAGGTTAGCGCTGCGGCGGCTGATATTAAGTGT 12013
 11655 CCCCCATGTGCGGCTCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 11714
 12014 GCGCATATGACTCCCATCATCTGGCGTTGCGATCTGACCAACACAAACCGCTGCTTACT 12073
 11715 GAATGCGATGAACAAATATGGGGCGCGGATGCACTGCACTATCGCAGTTTGGTGCA 11774
 12074 CAGTGAATGAACAAATATGGGGCTCATCACCCCTGCGTTTACCCTGAGTTTCCGCCCA 12133
 11775 GTTCTGGCTGGATGAAGAACCGAGCAGTGGCGGCGAGCAGTTCCTCTGCTGCTGCTTACCT 11834
 12134 GTTCTGGCTGGATGAAGAACCGAGCAGTGGATGCGGAGCAATATACAGTTTGTATCT 12193
 11835 GCAATTTACATTCATACCTGCTGCGGTTTGGTGGTGGCAGGATGAGATCACCGGTAACCG 11894
 12194 ACCCTTCCCGGTACACACCTTATGGCAACCGGAATAGAGGATGAATCAGCGGCAACAA 12253

QY	11895	TCTGGTCAGCGAGTCTTTATCGCACCGCGCTCTGGACGGCGAGGACGCGAGTTTCG	11954	QY	12777	AGTCTGGTATCTGGATTCAAGACGTTGCGACCGTCTCGCTCGCTCCGCCACCTCC	12836
Db	12254	ATTAGTCAACAATACTACTGATGACATCGCGCTGGGATGACGAGCGAGAAATTCG	12313	Db	13328	AACGTTTATACCGACGGGCAAAATGCAACGCCATCGCAACGCCAACACGACGCGCT	13387
QY	11955	GGGTTTGGTTTGTGAGATCAGGATACCGATACCTTTGGC-----	11996	QY	12837	GGTAGCTTTTATCGAAACGGCGCTGCTGGATGAGGGTATGGTCACTGCTGCGCTG	12896
Db	12314	CGGATTTGGTTATGTTGACAGAAAGACAGCCATCACTGGCCCAAGGCGAGTGGCCAGA	12373	Db	13388	GATTGCTTCACTCCGAGACACAGTATTATTAATCAATCCACACTATCAGCGTTTGTGGAG	13447
QY	11997	-----	11996	QY	12897	CATTGTGGATGAACAT-----CTCGACCAAGCGGTTTACCGGCAATCCGGATA	12944
Db	12374	ATGCACACCACTGCACTGACCCCAAGCAAGCGCCTGAACTCACATCACTCCCGCGCTGAC	12433	Db	13448	TATCTCATCTCTCAATTTGTCAACGACGCTGGAAACAGCGGATACCAAGCAACAGATT	13507
QY	11997	-----	11996	QY	12945	CCTTTTCCTCGAGCGAGGAAGCAGAACAGGCATTTGTGGATACCGCACCAGTGTCA	13004
Db	12434	CCAAGCAACGCTCCAGAACTCACACACCTGCGATGACCCAAAGCAACGCGCTGAACT	12493	Db	13508	TCTATTCCCGCGCACTGGAGAAGATAAG-----TCTGGCAGCTCGTCTGGGTATAC	13561
QY	11997	-----	11996	QY	13005	TACCTATCCCGCGGCGAGAGCAATTTCTGGCTACCGCTATCCCTTTTGGGACAGTAT	13064
Db	12493	-----	11996	Db	13562	TGATTAACGGCACAGCCGAACAGTTCTGGCGCGCCAAACAGAGCAACACTCAACTCAC	13621
QY	12494	CACATCACCCCGCTGACCCCAAGCAAGCGCCAGAAATTCACATCACCCCGCTGGCCCA	12553	QY	13065	CGGCCAGTTACCGTGACCGCTGACGCTGACGCTGCGCTCATCGCAGTGGCAGATGC	13124
QY	12003	GGGTACGGCGAAGCACTGATGATGCTTCTGTGAGCCGGAATCTGTATGCCACCGGGT	12062	Db	13622	GGGCAAAATACGCTCACTTGGGATGCAAACTATTGCGTGTGCTGACACAAACCCGGATGC	13681
Db	12554	AGGCAATGCGCCAGAACTCACACACCTGCGATGACCAAAATCTGTATGCCACCGGAAT	12613	QY	13125	CGCAGGATTTGACCAACAGCGCACTATGACTGGCGCTTCTGTGACGCGCGTCCGGGTGAC	13184
QY	12063	ACCGGAGTAGACGAGCGTCTGCGGAGACGATTTGGCAAAACGATGCCCGCTTTTGC	12122	Db	13682	GGCTGGACTGACAACTCAGCCAGATATGATTGGCGTTTCTGACCCCGCTTCAACTCAC	13741
Db	12614	ACCCATGATAGATAACACATTTATCGACAGAGTATTTGGCATGTGTGATCACCAAGCTTTGC	12673	QY	13185	GGACCCCAATGATATCTGCACTCGCTCATCGCTGCTGCGGCGGGGTGACCACTCT	13244
QY	12123	CGATTTCCGCAACCGCTTCACTGTGCTGCTGAGAGAGGATGAGCAGACATATCTCCGG-	12181	Db	13742	GGATTAACAGCAATCAGCACTTACCACGCTGTGATGCTGCGGCGGCAATCACACT	13801
Db	12674	CGGTTTTCACCAAGCTTTACGACCTGGCAAGATGGTCAAGATATTCTGCTCACACGGA	12733	QY	13245	CGGATTTGGGGACCGAAACCGGTAAGTACTGCTTATTTCTTACCGGAAAAATATC	13861
QY	12182	--ACGACAGCAAGACATCTGGTTGACGAGCGCCCTGAAAGGCACTCTGCTGCGCAGTGA	12239	Db	13862	GTTTCTCCACCATCTGATGTTGACGCGCGATTAAGTTAAACGCGCAATCCCTGTAGC	13921
Db	12734	AAATGATAACAGTCACTGCTGCTTAAACCCGGGCACTGAAAGGTCAACTGCTGACGAGTGA	12793	QY	13356	ACAGTGTCTGGTGTATGTCACGCGAGTTGG-----	13386
QY	12240	GTTATAGGTGCGGATCGCAGCAGCAGCGCGATATCCCTTACAGCGTCACTGAGTCTCG	12299	Db	13922	ACAGTGTCAAGTCTACGCAACCGCAAGCTGGATGCCCATATTAAAGAAAAACCTCAATAA	13981
Db	12794	ACTGTACGGCGAGGATGGCAGTACACAGGAAAAATTTCCCTTACACAGTCACTGAAATTCG	12853	QY	13387	-----	13386
QY	12300	CCCGCAGGTA---CGGCTAGTTGAAGCGAATGGAGACTACCCGCTGTGTGGCGGATGGG	12356	Db	13982	CCTGGCAGACGAGCGGAAAGAGTTATATACACCCGAAATCATCACCAGACGCGAGC	14041
Db	12854	CCACAGGTACGTCGGTTACAGCATACCGATAGCCGATACCTTGTGCTTTGGTCACTCTGT	12913	QY	13387	-----	13386
QY	12357	CGCGAAAGCGGTAGGTGATGAAACGCTACCAAGATGCTCAATGCCAACAGCA	12416	Db	14042	CATCTGTACCTAGCTCACCGCGCTGGGTAAAGCCAAAGTCAGTCACCCAGCCAAT	14101
Db	12914	AGTTGAAAGCGGCAACTATCATTAAGCAAGCTATCGCCAGCGATCTCAATGCGACGCAAAA	12973	QY	13387	-----	13386
QY	12417	GGCGTACTCTCAGTGATGAATACGGTTTCCCACTGCGTCAGGTCACTGTCMAATATCC	12476	Db	14102	CAATCTGTCAACCGCAGTCCCGCTTACCCCTCATAGCCTCAATGACTACGGATCG	14161
Db	12974	GATTACGCTATCCAGCGATCTATTGGTCAACCGGTAAACAGGTTTCGGTACAGTATCC	13033	QY	13443	CTATGACAGTGATAACCGGACAGCAGGTCCGCCAACAGGTGACATTCAGTGACCGTTTGG	13502
QY	12477	ACGACGCCCTCGTCCGCGGCAATCCATATCCGGGTCCTTACCGGCGAGCTGTTGCG	12536	Db	14162	TTATGACCGGATCTTAAAGCAACAGATTGTCACAAAGTAGTATTTCAGTGATGGCTTGG	14221
Db	13034	ACGCGCGCAGCAACCGGCAAGCAGTCCGTATCCCTGATACGTTGCTGATAGTTATTTCG	13093	QY	13503	CGGTGATTTGCAATCGGCAACCCCGGCGCGAGGCAACGCTGTGCAACAGGACGCGGA	13562
QY	12537	CAACAGTTTATGACGAGCAGCAGATATTAGCCTGGGTTGCAACAGCAGCAGTGACA	12596	Db	14222	CCGTTTACTGCAAGCATCTGTACGACATGAAGCAGCGGAAGCCTGCGCAACGTAACCAAGA	14281
Db	13094	TAAACAGTATGATGACCGAGCAACAAATTACGGCTCACCTATCAACAGTTTCAGTTGGCA	13153	QY	13563	CGGCAAACTGGTGAACCGGCGAGTGAACGATTGCGGTCAGTGACACGAAATTCGCTG	13622
QY	12597	TCACCTTGTTCCTGCTGAGGGGCAATTGGTTGTTGGGTTGGCGAGGGCTCGCGGA	12656	Db	14282	CGGCGCTCTGGTGACAAAAATGGA-----AGATACCAAAAAACGGCGCTG	14323
Db	13154	TCATCT-----GACCGCAATACCATTTCTGATGTTAGATTAACGGATAGTACCCGAG	13207	QY	13623	GGCGGTACCGGAGGCGGAGTATGACAAATAAGGTCTGCTGTTGCGGTTTATCAGCC	13682
QY	12657	CGATGTTTACGTACTCTGCGGACACAGTGCAGGAGGGGTTCTGACGCTGGACACCT	12716	Db	14324	GGCGGTACCGGACGCACTGAATATGACAAATAGGAGCAACCGATACGCACTATCAACC	14383
Db	13208	CGATATCTTTGCTTATAGCGCTGAACATGTCCTACTGCTGCTTAATCTTGGAAATCTCT	13267	QY	13683	GTATTTTCTGGACAGTTGGCAATATGTGATGATGACAGTGCCTGCGCCGCGAG-----	13736
QY	12717	GTTGGGCGCCGAAAGCTGCTCTCGGATAGTCAGGTGCGGTAGCTGCGGCGGTGACAGCA	12776	Db			
Db	13268	AAATGATAAAAATAGTCTGATTGCGGAGAAATAAAGCTCTGCTGAATACCTCGGCGCAGAAA	13327				

Db	14384	CTATTTCTCAACGACTGGCAATACGTCAGTAATGACAGTGCCTCGCGGACAGAAAGC	14443
Qy	13737	GTATGCCGACACGACCTTTTACGATCGACCGGACCGGAATGGCAGGTATTATACGGCAAA	13796
Db	14444	CTATGCGAGATACCATGCTATGATCCATTTGCTGAGAAATCAAGTCACTACCGCAAA	14503
Qy	13797	AGGTGAACGGGACGAGTGTGTATACCCCGTGGTTTGTGTGCTAGTGAAGACGAGAAATGA	13856
Db	14504	AGGCTGGTTCGTCGAACCTTTGTTCACTCCCTGGTTTACTGTCAATGAAGATGA	14563
Qy	13857	TACCGTTGGGCTAAACGACGATCCTGACTGGGAGGAGGGGGGAGCGGTGATGAGTCCG	13916
Db	14564	CACAGCT----ACTGAGGTGAAGGTAAAGAAAGAAATGTAAGAAAGGTAAAGAGGTA	14619
Qy	13917	TGCGCCCTGACAGGGCGCTGCTGATGGAGACAAAGATGAATACTACACTATCAGGTTGGC	13976
Db	14620	AAGATGTAATTTGATCAATCCCGCGGTTGAGGGCGGGAACAATACATATATAGAG	14679
Qy	13977	GCGGTTGTGCTGACAGGTGTTATGTTTGGGGCTTTCCCATTTGGCGTTACACCGTGGT	14036
Db	14680	G-----TGAAACGTTGCTATTAATGCTGCTGAGTACTCAACTTATGAGTTGGTT	14730
Qy	14037	TACACGCGGACGATCTCAATGGCAAAACCCGAGGCGGACAGGAAGGCGGATCGC	14096
Db	14731	GATCATTTGGTTTAT-----TGCGGCTTGGGGCGGATTAAGTACCTCATTG	14780
Qy	14097	TTGGCCCTCTGGCAGCAGAAACCCGGGAAAGATGGAGCAGCAGCAGACTGAC	14156
Db	14781	AT-----ATACAAACAAACAATGTAATTTGGAATTTGATCAAC-----GTACTCTGTC	14828
Qy	14157	ATGAACAAGTGGCTATACATGCTGAAGAAGAACTGGCTGTGCGCGTGAOCCTGCCGT	14216
Db	14829	AACTCAATATCTCTGTTTACCGGTATATGGGAGGACTGTGAGTTTGAAGCGGCG	14888
Qy	14217	GATGCTCAGCGCACTGGTCAGCGCTTGACGACACACCGTTACACCTCAGCGGCACTT	14276
Db	14889	GCAGCCCTATATGACTTTTGGCAATTTGCGGGCTATTTGGCCACCGGAAGTTCTGGAT	14948
Qy	14277	GCAGTGTGAACCCCGCGCTTTCCGAGCTTACCGCTATCGGTACAGACGACCTCGGA	14336
Db	14949	TGAATGTGATCTGGGTGGCTTTTATGCAATATCGC-----GATGATGGAGA	14998
Qy	14337	GGCCAAACCCGGCTTTTGTTCGCGAACTGTTCCGCGCGCTGACGAGAGCGGAGAG	14396
Db	14999	AAGCAATAGGCAATCCCACTGCGCAAAACCATCTGCTCGGCGATTAACACCGGAA	15058
Qy	14397	CTGCGAGCGTATGCTGACGAGCAGAGTGAATGGCAGGCTGCGGGCGGCTATCAG	14456
Db	15059	ATTACCTACTACACTATTGTAAGAAACGA-----ATATA	15094
Qy	14457	GCGCTACGACGAGGAGGAGGAGGATTAAGCGATTTAGCGGTTAAGGAAAGTGACGGTGT	14516
Db	15095	TAGAAAACCTAACATGAGATAAACCTGCGATGACAGACAGATGACACACGCGCC	15154
Qy	14517	TTTCGCGATTAATTAACAGGAGATCAATGACACATCTTGTTCAGTAGACCCCGT	14576
Db	15155	AACAACGAGGTAAT---CATGAAAAACATCGATCTTAACTTTATCAAAAGACCCCTGT	15211
Qy	14577	CGGTGCGGCTGCTGACAAACCGCGCTTGTGGTGGGAGCTGCGTACTACCGCCATC	14636
Db	15212	C-GTCAACATCTACGATAACCGAGGCTTAACGATCCGTAACAT---CGACTTTTCCCGTA	15267
Qy	14637	CGGATACACCGGAGGAGGAGGAGGATCACTGCTGACATCAGCAGATGAGCGCGCA	14696
Db	15268	CAACGCAACCGGAGATACGATATCCGTTATCTCGCCATCAATGACTCCCTTGGGC	15327
Qy	14697	GCTTGTCAAAAGCGCGACCGCGGTTACAGCGCGCGGTCTGACA---AATTTACGT	14753
Db	15328	ACCTAAGCAAGACCGATCCGCTCTATATGAAGCCAAACAAATCTAATTTCTCT	15387
Qy	14754	ACCTGAATAGCCTGACCGGACAGTACTGACAGGCTGACGCGGATCGCGTACGTCG	14813
Db	15388	GGCAGTATATTGACCGGTAATATTTTGTGTACAGAAAGCGTCAATGCTGGTGCACGT	15447
Qy	14814	TGGAATCAGCGATGCGCCCGGGGGGTTTGGCCGTCACCGGGGCTGGGACGGAAG	14873
Db	15448	TCACCTTGAATGATATTGAAGCGCTCCGCTACTGACAGTAACTGCAACAGG-----	15499
Qy	14874	ACGCGGTACCCGCACTTGGCAATATGAAGACGATACCTCGCGGGCGCGCTGAGCA	14933
Db	15500	----TGTCTATACAAACCGGACATATGAACGCTCTTCCCTACCCGCTGCTGTGTTCTG	15555
Qy	14934	TCACGAGCAGGTTACCGGTGAAGCGGCCCAATTTACGGAACGCTTCGTGTAGCTGGCA	14993
Db	15556	TTACCGAAACAATACAGAAAAACATCCCGTATCACGAAACGCTGATTTGGGCTGGCA	15615
Qy	14994	ATACGATCCGAGAGATTTCTCAATCTGGCTGGCGGAGTGTCTAGTCAATTAAGTACCG	15053
Db	15616	ATAGCGAAGCAGAAAAAACCAATAATCTTGCCAGCCAGTGTGCTGGCCACTATGACACG	15675
Qy	15054	CGGACTGTGACAGCAGCAGCATCGCCCTGAGCGCGCTGCGCTGCGCGTACCGCGC	15113
Db	15676	CGGAGTCAACCGATTAGAGATTTGTCTACTGACCGGTACTGTTTATCTCAATCCAGCC	15735
Qy	15114	AGTTGCTGCCGACGCGCGGGGGCCAACTGGATGGGTGAGGATGCTCGGCTGGAATG	15173
Db	15736	AACTATTGACGACACTCAAGAACTAGCTGGACAGTGTATTAAGAACCGTCTGCGCAA	15795
Qy	15174	ACCTGCTGGATGGGAGACGTTCTTCCACCCAGACCCACCGCTGATGCGACCGCGCGCTCC	15233
Db	15796	ACATGCTGGCTGATGACATCTACAAACCTGAGCGCTTTGATGACCCCGCGCTTAC	15855
Qy	15234	TGAGCATCCGATGCAAAAGTAATCTGACGCGTGTGGCATATGATGTGGCTGGGCTGC	15293
Db	15856	TCATCAGACGATGCGAAAGGGAACATTACAGAGGCTAACCTATGATGTGGCGGGCAGC	15915
Qy	15294	TATCGGCGAGTGTGTGACGCTGAAGGAACGCGACGAGAGGTCATCGTGGCCCTCCCTGA	15353
Db	15916	TAAACGGGAGCTGGTTAACTTAAAGACCAACCGGAAACCAAGTGATTTATCAGATCCCTGA	15975
Qy	15354	CGTACTCGCGCGCGGAAAGATTTGCTGAAGAACACGCAACGCGCTGTTAACTTCGT	15413
Db	15976	CCTATTCCGCGCGGACAAATAATTCGAGAGAACCGGCAATGCTGTGTTATACCGAAT	16035
Qy	15414	ATATTTACGACCGGAAACACAGCGCTGACGGGATTTAAACGGAACGCTCGCTGGGC	15473
Db	16036	ACGTTATGAACCGGAAACCCAAACAGCTTATCGGTACCAAAACCCACCGCTCGTCAGAT-	16094
Qy	15474	ACGTTGCGGAGCAAAAGTGTGACGAGACCTGCGCTATACGTATGATACCGGTGACCAACG	15533
Db	16095	-----GCCAAAGTGTGCAAGATCTACGTTATGATATGACCCCGGTAGGCAATG	16143
Qy	15534	TACTCAGGCTCAATTAACGATCGGAAAGACCCGCTTCTGGCGTAAACGAGAAAGTGGTAC	15593
Db	16144	TCATCAGTATCGTAAATGACGAGAGCCACCCGCTTCTGGCAACATCAGAAAGTGGCGC	16203
Qy	15594	CGGAGAAATACGTATCTACGACAGCTGTACAGCTGTCAGCGCCACAGGGCGTGAGA	15653
Db	16204	CGGAAACACTTATACCTACGACTCTCTGTATCAGCTTATCAGCGCAACCGCGCGAGA	16263
Qy	15654	TGGCAATCGCGCGCAGCGGCAACGACTTACCATCCGCTACAGCCCGCTTCTCTACAG	15713
Db	16264	TGGCAATATAGGTGAGCAAAAGTAACCACTTCCCTCC-----CTCACCTTACCTTCTG	16317
Qy	15714	ACAGCTCTGCTTACCACTTACGCGCACCTACCGTTTATGACCGTGTGGGCAACCTGA	15773
Db	16318	ATAACAAACCTTACCACTTATACCCGTACTTATCTTATGACCGTGGGCGCAATTTGA	16377
Qy	15774	CGCAGATGGCGCACAGTGGCCCTGCGCAACGAAACAAATTAATTAACGACAGACATCACGTTA	15833
Db	16378	CTAAATCAGACACAGTTCAACCGCGACGCAAAACAACTACACCAACAAACATCACGTTT	16437
Qy	15834	GTACCCGAGCAATATAGGGCGGTACTGAGCAAGTGTGGGCAAGTGGCTCAGATGTTGATA	15893
Db	16438	CTAACCGGAGCAATCGCGAGTACTCAGCACTCTGACCGAAGATCCGCGCGAGTAGATG	16497

